<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945811</url>
  </required_header>
  <id_info>
    <org_study_id>CMHQ3</org_study_id>
    <nct_id>NCT04945811</nct_id>
  </id_info>
  <brief_title>Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta</brief_title>
  <official_title>Role of Interleukin-6 and Procalcitonin in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FARAH AFZAL</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Combined Military Hospital, Pakistan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serum Interleukin-6 and Procalcitonin of 100 consenting COVID 19 positive patients from April&#xD;
      2020 - May 2021 were assessed at Pathology department CMH Quetta and the results were&#xD;
      correlated with severity of lung involvement on HRCT Chest&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To explore the relation between Interleukin-6 and Procalcitonin with COVID&#xD;
      severity on HRCT Chest Study Design: Randomized Control Trial (Clinical Trials. gov&#xD;
      Identifier: NCT04798391) Place and duration of study: Pathology, Radiology &amp; ENT Department&#xD;
      CMH Quetta from April 2020 - May 2021 Methodology: Serum Interleukin-6 and Procalcitonin of&#xD;
      100 consenting COVID 19 positive patients from April 2020 - May 2021 were assessed at&#xD;
      Pathology department CMH Quetta and the results were correlated with severity of lung&#xD;
      involvement on HRCT Chest Results: Serum Interlukin-6 levels were raised in 97 (97%) patients&#xD;
      with mean levels of 20.43 + 19.66 (pg/ml). Serum procalcitonin levels were raised in 95 (95%)&#xD;
      patients with mean levels of 0.4331 + 0.24 (ng/ml). A P value of &lt;0.001 was calculated on&#xD;
      Independent Sample T-test for both serum interlukin-6 and serum procalcitonin as correlated&#xD;
      with severity of lung involvement on HRCT Chest.&#xD;
&#xD;
      Conclusion: Interlukin-6 and procalcitonin are excellent biomarkers for diagnosis and&#xD;
      predicting severity of COVID19 pneumonia.&#xD;
&#xD;
      Keywords: Covid19 pneumonia, Interlukin-6, procalcitonin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">May 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of inflammatory biomarkers is raised in accordance with severity of COVID 19</measure>
    <time_frame>2 days</time_frame>
    <description>serum Interlukin-6 levels was measured on COBAS-e 411 Immunoassay analyzer using electro chemiluminescence methodology using Roche Interlukin-6 kit with raised levels taken as &gt; 7 pico gram / milliliter (pg/ml). Serum procalcitonin were also measured by similar methodology using Roche procalcitonin kit with raised levels taken as &gt; 0.15 nano gram / milliliter (ng/ml).&#xD;
COVID 19 pneumonia was categorized on HRCT chest as Mild with total score 7 or less, moderate with score from 8 - 17, and severe with score more than 18.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Covid19 Positive Patients</condition>
  <arm_group>
    <arm_group_label>Interlukein 6 and procalcitonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interlukein 6 and procalcitonin levels in COVID 19 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Interlukein 6 and procalcitonin serum levels</intervention_name>
    <description>Blood tests</description>
    <arm_group_label>Interlukein 6 and procalcitonin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  positive PCR of COVID 19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NEGATIVE PCR of COVID 19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>38 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cmh Quetta</name>
      <address>
        <city>Quetta</city>
        <state>Balochistan</state>
        <zip>1234</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Combined Military Hospital, Pakistan</investigator_affiliation>
    <investigator_full_name>FARAH AFZAL</investigator_full_name>
    <investigator_title>CLASSIFIED SPECIALIST</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

